Related references
Note: Only part of the references are listed.A phase I study of pexidartinib, a colony-stimulating factor 1 receptor inhibitor, in Asian patients with advanced solid tumors
Jih-Hsiang Lee et al.
INVESTIGATIONAL NEW DRUGS (2020)
Multiple systemic treatment options in a patient with malignant tenosynovial giant cell tumour
Sara Elena Rebuzzi et al.
ANTI-CANCER DRUGS (2020)
Colony-Stimulating Factor-1 Antibody Lacnotuzumab in a Phase 1 Healthy Volunteer Study and Mechanistic Investigation of Safety Outcomess
Francois Pognan et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2019)
Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial
William D. Tap et al.
LANCET (2019)
Multidisciplinary care in tenosynovial giant cell tumours
William D. Tap
LANCET ONCOLOGY (2019)
Surgical outcomes of patients with diffuse-type tenosynovial giant-cell tumours: an international, retrospective, cohort study
Monique J. L. Mastboom et al.
LANCET ONCOLOGY (2019)
Long-term efficacy of imatinib mesylate in patients with advanced Tenosynovial Giant Cell Tumor
F. G. M. Verspoor et al.
SCIENTIFIC REPORTS (2019)
A case report of vanishing bile duct syndrome after exposure to pexidartinib (PLX3397) and paclitaxel
Sorbarikor Piawah et al.
NPJ BREAST CANCER (2019)
Drug-induced bile duct injury
Michele Visentin et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2018)
Nilotinib in locally advanced pigmented villonodular synovitis: a multicentre, open-label, single-arm, phase 2 trial
Hans Gelderblom et al.
LANCET ONCOLOGY (2018)
Risk factors for erlotinib-induced hepatotoxicity: a retrospective follow-up study
Min Kyoung Kim et al.
BMC CANCER (2018)
Clinical characteristics and treatment outcomes in six cases of malignant tenosynovial giant cell tumor: initial experience of molecularly targeted therapy
Robert Nakayama et al.
BMC CANCER (2018)
Current Systemic Treatment Options for Tenosynovial Giant Cell Tumor/Pigmented Villonodular Synovitis: Targeting the CSF1/CSF1R Axis
Mehdi Brahmi et al.
CURRENT TREATMENT OPTIONS IN ONCOLOGY (2016)
Diffuse-type tenosynovial giant cell tumour: Current treatment concepts and future perspectives
Eric L. Staals et al.
EUROPEAN JOURNAL OF CANCER (2016)
The Art and Science of Diagnosing and Managing Drug-induced Liver Injury in 2015 and Beyond
James H. Lewis
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2015)
Tenosynovial giant cell tumour/pigmented villonodular synovitis: Outcome of 294 patients before the era of kinase inhibitors
Emanuela Palmerini et al.
EUROPEAN JOURNAL OF CANCER (2015)
Features and Outcomes of 899 Patients With Drug-Induced Liver Injury: The DILIN Prospective Study
Naga Chalasani et al.
GASTROENTEROLOGY (2015)
Results from a Phase IIA Parallel Group Study of JNJ-40346527, an Oral CSF-1R Inhibitor, in Patients with Active Rheumatoid Arthritis despite Disease-modifying Antirheumatic Drug Therapy
Mark C. Genovese et al.
JOURNAL OF RHEUMATOLOGY (2015)
CSF1R inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue: a dose-escalation and dose-expansion phase 1 study
Philippe A. Cassier et al.
LANCET ONCOLOGY (2015)
Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor
W. D. Tap et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Formation of reactive metabolites and management of tyrosine kinase inhibitor-induced hepatotoxicity: a literature review
Yi Ling Teo et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2015)
ACG Clinical Guideline: The Diagnosis and Management of Idiosyncratic Drug-Induced Liver Injury
Naga P. Chalasani et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2014)
Drug-Induced Liver Injury, Dosage, and Drug Disposition: Is Idiosyncrasy Really Unpredictable?
James H. Lewis
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2014)
Drug-Induced Liver Injury: Morbidity, Mortality, and Hy's Law
Arie Regev et al.
GASTROENTEROLOGY (2014)
Risk of tyrosine kinase inhibitors-induced hepatotoxicity in cancer patients: A meta-analysis
Yi Ling Teo et al.
CANCER TREATMENT REVIEWS (2013)
Hepatotoxicity of Tyrosine Kinase Inhibitors: Clinical and Regulatory Perspectives
Rashmi R. Shah et al.
DRUG SAFETY (2013)
High Lipophilicity and High Daily Dose of Oral Medications Are Associated With Significant Risk for Drug-Induced Liver Injury
Minjun Chen et al.
HEPATOLOGY (2013)
Pigmented villonodular synovitis therapy with MSCF-1 inhibitors
H. Thomas Temple
CURRENT OPINION IN ONCOLOGY (2012)
Treatment of tenosynovial giant cell tumor and pigmented villonodular synovitis
Vinod Ravi et al.
CURRENT OPINION IN ONCOLOGY (2011)
Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: Search for signals
Craig Lammert et al.
HEPATOLOGY (2008)
Share Paper
